Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments
The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).
1. A polynucleotide encoding a heavy chain variable region (HCVR) of an antibody or antigen-binding fragment thereof that binds a SARS-CoV-2 spike protein comprising the amino acid sequence set forth in SEQ ID NO: 832, wherein said HCVR comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3), wherein said HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 204, said HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 206, and said HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 208.
2. The polynucleotide of claim 1 , wherein said HCVR comprises the amino acid sequence set forth in SEQ ID NO: 202.
3. The polynucleotide of claim 1 , wherein said polynucleotide comprises an HCDR1 nucleic acid sequence set forth in SEQ ID NO: 203, an HCDR2 nucleic acid sequence set forth in SEQ ID NO: 205, and an HCDR3 nucleic acid sequence set forth in SEQ ID NO: 207.
4. The polynucleotide of claim 1 , wherein said polynucleotide comprises an HCVR nucleic acid sequence set forth in SEQ ID NO: 201.
5. The polynucleotide of claim 1 , wherein said antibody further comprises an immunoglobulin constant region.
6. The polynucleotide of claim 5 , wherein said immunoglobulin constant region is an IgG1 constant region.
7. The polynucleotide of claim 1 , wherein said antibody comprises a heavy chain amino acid sequence set forth in SEQ ID NO: 216.
8. The polynucleotide of claim 1 , wherein said polynucleotide comprises a heavy chain nucleic acid sequence set forth in SEQ ID NO: 215.
9. The polynucleotide of claim 1 , wherein said polynucleotide is an RNA polynucleotide.
10. A vector or lipid nanoparticle comprising the polynucleotide of claim 1 .
11. The vector of claim 10 , wherein said vector is a lentivirus vector or an adeno-associated virus vector.
12. A polynucleotide encoding a light chain variable region (LCVR) of an antibody or antigen-binding fragment thereof that binds a SARS-CoV-2 spike protein comprising the amino acid sequence set forth in SEQ ID NO: 832, wherein said LCVR comprises three light chain complementarity determining regions (CDRs) (LCDR1, LCDR2 and LCDR3), wherein said LCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 212, said LCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 55, and said LCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 214.
13. The polynucleotide of claim 12 , wherein said LCVR comprises the amino acid sequence set forth in SEQ ID NO: 210.
14. The polynucleotide of claim 12 , wherein said polynucleotide comprises an LCDR1 nucleic acid sequence set forth in SEQ ID NO: 211, an LCDR2 nucleic acid sequence set forth in SEQ ID NO: 54, and an LCDR3 nucleic acid sequence set forth in SEQ ID NO: 213.
15. The polynucleotide of claim 12 , wherein said polynucleotide comprises an LCVR nucleic acid sequence set forth in SEQ ID NO: 209.
16. The polynucleotide of claim 12 , wherein said antibody comprises a light chain amino acid sequence set forth in SEQ ID NO: 218.
17. The polynucleotide of claim 12 , wherein said polynucleotide comprises a light chain nucleic acid sequence set forth in SEQ ID NO: 217.
18. The polynucleotide of claim 12 , wherein said polynucleotide is an RNA polynucleotide.
19. A vector or lipid nanoparticle comprising the polynucleotide of claim 12 .
20. The vector of claim 19 , wherein said vector is a lentivirus vector or an adeno-associated virus vector.